In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Enzyme Inhibition and Medicinal Chemistry

• Publication date

  2016-01-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/14756366.2015.1005011PMID 26083304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.

  2014cited by this paper
• an update on

  2014cited by this paper
• Designing of multi-targeted molecules using combination of molecular screening and in silico drug cardiotoxicity prediction approaches.

  2014cited by this paper
• Structure Driven Design of Novel Human Ether-A-Go-Go-Related-Gene Channel (hERG1) Activators

  2014cited by this paper
• Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

  2013cited by this paper
• Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.

  2013cited by this paper
• Identification of novel PARP-1 inhibitors by structure-based virtual screening.

  2013cited by this paper
• The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease.

  2012cited by this paper
• Structure-Guided Topographic Mapping and Mutagenesis to Elucidate Binding Sites for the Human Ether-a-Go-Go-Related Gene 1 Potassium Channel (KCNH2) Activator NS1643

  2012cited by this paper
• New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

  2012cited by this paper
• Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding

  2012cited by this paper
• CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling.

  2011cited by this paper
• Strategies in the rational drug design.

  2011cited by this paper
• Atomistic models for free energy evaluation of drug binding to membrane proteins.

  2011cited by this paper
• PARP inhibitors in breast cancer: BRCA and beyond.

  2011cited by this paper
• Structural refinement of the hERG1 pore and voltage‐sensing domains with ROSETTA‐membrane and molecular dynamics simulations

  2010cited by this paper
• Drug-like Bioactive Structures and Conformational Coverage with the LigPrep/ConfGen Suite: Comparison to Programs MOE and Catalyst

  2010cited by this paper
• Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

  2010cited by this paper
• Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.

  2010cited by this paper
• Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.

  2009cited by this paper
• Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study

  2009cited by this paper
• Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.

  2009cited by this paper
• Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity

  2008cited by this paper
• DrugBank and its relevance to pharmacogenomics.

  2008cited by this paper
• Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.

  2008cited by this paper
• Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

  2008cited by this paper
• Recent developments in de novo design and scaffold hopping.

  2008cited by this paper
• Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.

  2007cited by this paper
• Bio3d: an R package for the comparative analysis of protein structures

  2006cited by this paper
• ART2, a T Cell Surface Mono-ADP-ribosyltransferase, Generates Extracellular Poly(ADP-ribose)*

  2006cited by this paper
• New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.

  2006cited by this paper
• Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.

  2005cited by this paper
• Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone.

  2005cited by this paper
• Very fast empirical prediction and rationalization of protein pKa values

  2005cited by this paper
• Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.

  2004cited by this paper
• Phase II trial with oral idarubicin in advanced breast cancer

  2004cited by this paper
• A hierarchical approach to all‐atom protein loop prediction

  2004cited by this paper
• The PARP superfamily

  2004cited by this paper
• Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

  2004cited by this paper
• Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones.

  2003cited by this paper
• PARP goes transcription.

  2003cited by this paper
• Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update

  2002cited by this paper
• Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.

  2001cited by this paper
• Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors.

  2001cited by this paper
• Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

  1999cited by this paper
• The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis.

  1998cited by this paper
• Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.

  1998cited by this paper
• Glutamic Acid 207 in Rodent T-cell RT6 Antigens Is Essential for Arginine-specific ADP-ribosylation*

  1996cited by this paper
• NAMD: a Parallel, Object-Oriented Molecular Dynamics Program

  1996cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.

  1996cited by this paper
• The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

  1995cited by this paper
• Cluster analysis of molecular conformations

  1994cited by this paper
• Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models

  1992cited by this paper
• Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase.

  1991cited by this paper
• LIII. On lines and planes of closest fit to systems of points in space

  1901cited by this paper

• Mathematical modeling of cardio-oncology: modeling the systemic effects of cancer therapeutics on the cardiovascular system.

  2023cites this paper
• How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level

  2023cites this paper
• In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of Triple-negative breast cancer.

  2023cites this paper
• Evaluation of anticancer activity of N-H/N-Me Aziridine derivatives as a potential poly (ADP-ribose) polymerase 1 inhibitor

  2022cites this paper
• Deciphering the functional mechanism of zinc ions of PARP1 binding with single strand breaks and double strand breaks

  2022cites this paper
• Biochemical, Structural Analysis, and Docking Studies of Spiropyrazoline Derivatives

  2022cites this paper
• TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.

  2021influential citation
• Discovery of New Protein Targets of BPA Analogs and Derivatives Associated with Noncommunicable Diseases: A Virtual High-Throughput Screening

  2021cites this paper
• Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer

  2021cites this paper
• An Insight of RuBisCO Evolution through a Multilevel Approach

  2021cites this paper
• Could the spanning of NAM-AD subsites by poly (ADP ribose) polymerase inhibitors potentiate their selective inhibitory activity in breast cancer treatment? Insight from biophysical computations

  2021cites this paper
• Predicting PARP inhibitory activity – A novel quantum mechanical based model

  2020influential citation
• Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches

  2020cites this paper
• Investigating the Mechanistic Inhibitory Discrepancies of Novel Halogen and Alkyl Di‐Substituted Oxadiazole‐Based Dibenzo‐Azepine‐Dione Derivatives on Poly (ADP‐Ribose) Polymerase‐1

  2020cites this paper
• Insight into the binding of a synthetic nitro-flavone derivative with human poly-ADP ribose polymerase 1.

  2019cites this paper
• Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.

  2018cites this paper
• Target-based drug discovery through inversion of quantitative structure-drug-property relationships and molecular simulation: CA IX-sulphonamide complexes

  2018cites this paper
• Identification of potential inhibitors of PARP-1, a regulator of caspase-independent cell death pathway, from Withania somnifera phytochemicals for combating neurotoxicity: A structure-based in-silico study

  2017cites this paper
• Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism

  2017cites this paper
• Synthesis, biological activity and multiscale molecular modeling studies for coumaryl-carboxamide derivatives as selective carbonic anhydrase IX inhibitors

  2017cites this paper
• Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies

  2017cites this paper
• Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.

  2016cites this paper